Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Consumption of green tea has been associated with reduced risk of breast cancer. Hormonal modulation has been suggested as one of the potential underlying mechanisms; however, it has yet to be fully elucidated in large, long-term human clinical trials.

Objective: We investigated the effects of decaffeinated green tea extract (GTE) on circulating sex hormones and insulin-like growth factor (IGF) proteins.

Methods: We conducted a placebo-controlled double-blind randomized clinical trial recruiting from 8 clinical centers in Minnesota. Participants were 538 healthy postmenopausal women randomly assigned to the GTE group (463 completed the study; mean age = 60.0 y) and 537 to the placebo group (474 completed; mean age = 59.7 y). Women in the GTE group orally took 4 decaffeinated capsules containing 1315 mg total catechins including 843 mg epigallocatechin-3-gallate daily for 1 y, whereas women in the placebo group took similar capsules containing no tea catechins. Blood sex hormones (estrone, estradiol, androstenedione, testosterone, and sex hormone-binding globulin) and IGF proteins (IGF-1 and IGF binding protein-3) were quantified at baseline and months 6 (for IGF proteins only) and 12, and were assessed as secondary outcomes of the study using a mixed-effect repeated-measures ANOVA model.

Results: Women in the GTE group had significantly higher blood total estradiol (16%; P = 0.02) and bioavailable estradiol (21%; P = 0.03) than in the placebo group at month 12. There was a statistically significant interaction between GTE supplementation and duration of treatment on estradiol and bioavailable estradiol (both Ps for interaction = 0.001). The catechol-O-methyltransferase genotype did not influence blood sex hormones before or after GTE supplementation. The circulating concentrations of IGF proteins were comparable between GTE and placebo groups at all 3 time points.

Conclusion: These results suggest that a 12-mo GTE supplementation significantly increases circulating estradiol concentrations in healthy postmenopausal women. This trial was registered at clinicaltrials.gov as NCT00917735.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461722PMC
http://dx.doi.org/10.1093/jn/nxy316DOI Listing

Publication Analysis

Top Keywords

sex hormones
16
green tea
12
postmenopausal women
12
gte group
12
placebo group
12
igf proteins
12
gte supplementation
12
circulating sex
8
hormones insulin-like
8
insulin-like growth
8

Similar Publications

Background: The link between exposure to environmental hazards and thyroid function has been relatively well established. However, evidence on environmental exposure to volatile organic compounds (VOCs) and thyroid function in the general population remains unclear.

Objectives: To assess the impact of individual and joint effects of VOCs exposure on thyroid function in a representative sample of U.

View Article and Find Full Text PDF

Objective: This post hoc study of the Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment (ProTECT) III trial investigates whether improving traumatic brain injury (TBI) classification, using serum biomarkers (glial fibrillary acidic protein [GFAP] and ubiquitin carboxyl-terminal esterase L1 [UCH-L1]) and algorithmically assessed total lesion volume, could identify a subset of responders to progesterone treatment, beyond broad measures like the Glasgow Coma Scale (GCS) and Glasgow Outcome Scale-Extended (GOS-E), which may fail to capture subtle changes in TBI recovery.

Design: Brain lesion volumes on CT scans were quantified using Brain Lesion Analysis and Segmentation Tool for CT. Patients were classified into true-positive and true-negative groups based on an optimization scheme to determine a threshold that maximizes agreement between radiological assessment and objectively measured lesion volume.

View Article and Find Full Text PDF

Kidney Health and Gender-Affirming Hormone Therapy for Transgender and Gender Diverse Individuals.

Clin J Am Soc Nephrol

September 2025

VA Greater Los Angeles Health Care System, Department of General Internal Medicine, Department of Medicine.

This review examines the effects of gender-affirming hormone therapy (GAHT) on kidney health in transgender and gender diverse (TGD) populations, which face significant challenges in accessing medical care. GAHT, typically involves estrogen therapy for transgender women and transfeminine individuals, testosterone therapy for transgender men and transmasculine individuals, and therapy regimens for individuals who are nonbinary or identify with another gender not culturally assigned to their sex assigned at birth. Hormone therapy influences biomarkers such as creatinine and cystatin C, which are used in estimating glomerular filtration rate (eGFR).

View Article and Find Full Text PDF

The current study aimed to determine the impacts of hCG injection on the reproductive performance and hormonal profile of senile camels. Ten adult senile camels were classified into two groups: control males (n = 5) and treated males (n = 5; received hCG) once/week. Testicular morphology and echotexture [testicular volume (TV), testicular echogenicity (TE), and pixel heterogeneity (PH)] were measured.

View Article and Find Full Text PDF

[Clinical efficacy analysis of Shibao Decoction in the treatment of late-onset hypogonadism with kidney essence deficiency].

Zhonghua Nan Ke Xue

July 2025

Department of Surgery, Yinchuan Hospital of Traditional Chinese Medicine, Ningxia Medical University, Yinchuan, Ningxia 750001, China.

Objective: To evaluate the clinical efficacy of "Shibao Decoction" in the management of late-onset hypogonadism (LOH) caused by deficiency of kidney essence.

Methods: Sixty male patients with late-onset hypogonadism of kidney essence deficiency type were randomly assigned to the treatment group and the control group, each with 30 cases. The patients in treatment group were treated with oral Shibao Decoction, while the control group was treated with oral Testosterone Undecanoate Capsules.

View Article and Find Full Text PDF